We are live on ! Find out more
BRA

Bender Robert & Associates Portfolio holdings

AUM $417M
1-Year Est. Return 25.02%
This Fund
S&P 500
This Quarter Est. Return
+14.38%
1 Year Est. Return
+25.02%
3 Year Est. Return
+98.12%
5 Year Est. Return
+139.29%
10 Year Est. Return
+812.75%
AUM
$352M
AUM Growth
+$41.1M
Cap. Flow
+$183K
Cap. Flow %
0.05%
Top 10 Hldgs %
71.31%
Holding
57
New
1
Increased
27
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$3.01M
2
AMD icon
Advanced Micro Devices
AMD
+$846K
3
MSFT icon
Microsoft
MSFT
+$460K
4
AMZN icon
Amazon
AMZN
+$382K
5
FIVE icon
Five Below
FIVE
+$243K

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.99M
2
URGN icon
UroGen Pharma
URGN
+$606K
3
T icon
AT&T
T
+$358K
4
CLVS
Clovis Oncology, Inc.
CLVS
+$351K
5
EOLS icon
Evolus
EOLS
+$325K

Sector Composition

Rank Sector Weight
1 Technology 33.5%
2 Consumer Discretionary 28.93%
3 Healthcare 22.13%
4 Communication Services 12.42%
5 Industrials 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLSE icon
51
Pulse Biosciences
PLSE
$2.27B
– –
-8,825
Closed -$209K
SMMT icon
52
Summit Therapeutics
SMMT
$10.5B
– –
-14,059
Closed -$83K
T icon
53
AT&T
T
$167B
– –
-15,660
Closed -$358K
URGN icon
54
UroGen Pharma
URGN
$2.02B
– –
-31,131
Closed -$606K
CMRX
55
DELISTED
Chimerix, Inc.
CMRX
– –
-10,000
Closed -$96K
JNCE
56
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-10,000
Closed -$103K
CLVS
57
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-50,000
Closed -$351K
1 2
3

Similar funds

AWCI
Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return
KPWG
KFA Private Wealth Group Tysons, Virginia $417M AUM 16.82% 1-Year Est. Return
ACM
Alight Capital Management New York $417M AUM 98.18% 1-Year Est. Return
PA
PSI Advisors Tampa, Florida $418M AUM 15.55% 1-Year Est. Return
CEI
Clark Estates Inc New York $416M AUM 6.04% 1-Year Est. Return
MCM
Millstreet Capital Management Boston, Massachusetts $418M AUM 80.77% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SCP
Stevens Capital Partners Omaha, Nebraska $416M AUM 18.93% 1-Year Est. Return

Bender Robert & Associates's Q2 2021 Portfolio in Review

As of Q2 2021, Bender Robert & Associates held 57 positions worth $352M, up 13% from $311M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Bender Robert & Associates's Q2 2021 filing shows 1 new, 27 increased, 11 reduced and 10 closed positions. Its largest new stake was Advanced Micro Devices: 10,468 shares worth $983K. The largest sale was Alphabet (Google) Class C, an estimated $2.99M.

By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Bender Robert & Associates's largest Q2 2021 buy was Advanced Micro Devices: 10,468 shares worth $983K.
  • Bender Robert & Associates added most to Alphabet (Google) Class A in Q2 2021, an estimated $3.01M increase.
  • Bender Robert & Associates's biggest Q2 2021 reduction was Alphabet (Google) Class C, cutting an estimated $2.99M.
  • Bender Robert & Associates fully exited UroGen Pharma in Q2 2021, selling an estimated $606K.
  • Bender Robert & Associates's ten largest holdings make up 71% of its $352M portfolio in Q2 2021.
  • Bender Robert & Associates opened 1 new position and closed 10 in Q2 2021.
  • Bender Robert & Associates's portfolio value rose 13% quarter-over-quarter to $352M.

Based on Bender Robert & Associates's 13F filing for Q2 2021, filed 16 Jul 2021.